Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

484 Press Releases
DateTitleCompany
20 Jul 17 NICE Recommends CINQAERO® (reslizumab) for the Treatment of Severe Eosinophilic Asthma Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
13 Jul 17 Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Jul 17 Teva to Report Second Quarter 2017 Financial Results on August 3, 2017 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
11 Jul 17 Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO™ (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
29 Jun 17 Teva Announces Publication of AIM-TD Study Results in The Lancet Psychiatry for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
29 Jun 17 Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab) Teva Pharmaceutical Industries Ltd. and Celltrion, Inc.,
Published by
Business Wire
27 Jun 17 Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc.,
Published by
Business Wire
12 Jun 17 Teva Announces Launch of Generic Zetia® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
09 Jun 17 Teva Announces Exclusive Launch of Generic Pataday® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
07 Jun 17 Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase III Study in Episodic Migraine Prevention Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Jun 17 Teva to Present at the Jefferies 2017 Global Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
01 Jun 17 Teva to Present Data from 18 Abstracts in Tardive Dyskinesia and Huntington Disease at the 21st International Congress of Parkinson’s Disease and Movement Disorders Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
31 May 17 Teva Announces Positive Results for Phase III Study of Fremanezumab for the Prevention of Chronic Migraine Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
17 May 17 Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual Meeting Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
15 May 17 Teva Announces Launch of Generic Glumetza® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
15 May 17 Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125) Teva Pharmaceutical Industries, Ltd.,
Published by
Business Wire
05 May 17 Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
05 May 17 Teva Announces Publication of COPAXONE® (glatiramer acetate injection) Pregnancy Data in the International Journal of MS Care Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
02 Feb 17 Teva Confirms Generic Victoza® Patent Challenge in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Mar 17 Teva to Present at the Cowen & Company 37th Annual Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
01 Mar 17 Teva Announces Launch of Generic Pristiq® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
16 Mar 17 Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Apr 17 Teva to Report First Quarter 2017 Financial Results on May 11, 2017 Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
26 Apr 17 Teva Announces Launch of Generic Vytorin® in the United States Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
28 Feb 17 Teva Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive Dyskinesia Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
06 Feb 17 Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
13 Mar 17 Teva to Present at the Barclays Global Annual Healthcare Conference Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
27 Apr 17 Teva Announces Publication of ARM-TD Study Results in Neurology® for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
26 Apr 17 Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
04 Apr 17 Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease Teva Pharmaceutical Industries Ltd.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.